Stella Gagliardi

By Cristina Cereda, Stella Gagliardi, Emanuela Cova, Luca Diamanti and Mauro Ceroni

Part of the book: Amyotrophic Lateral Sclerosis

By L. Diamanti, S. Gagliardi, C. Cereda and M. Ceroni

Part of the book: Current Advances in Amyotrophic Lateral Sclerosis

By Orietta Pansarasa, Stella Gagliardi, Daisy Sproviero and Cristina Cereda

Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disorder characterized by the selective death of upper and lowers motor neurons in spinal cord, brain stem, and motor cortex, which leads to paralysis and death within 2–3 years of onset. Deeply sequencing technologies, to simultaneously analyze the transcriptional expression of thousands of genes, offered new possibilities to focus on ALS pathogenesis and, most notably, to find new potential targets for novel treatments. The present book chapter illustrates recent advances in transcriptomic studies in animal models and human samples and in new molecular targets related to ALS pathogenesis and disease progression. Additionally, new insights into the involvement of altered transcriptional profiles of noncoding RNAs (microRNA and lncRNA) and ALS-associated ribosomal binding proteins have been investigated, to understand the functional consequences of extensive RNA dysregulation in ALS. Attention has been also turned on how transcriptome alterations could highlight new molecular targets for drug development.

Part of the book: Amyotrophic Lateral Sclerosis